Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Takimoto

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|January 5, 2026
Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activityXueyuan Zhou, Felix Klaus Geyer, Jeffrey Takimoto, et al.
Frontiers in Immunology|March 8, 2024
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engagerXueyuan Zhou, Felix Klaus Geyer, Dominic Happel, et al.
Antibodies (Basel, Switzerland)|September 22, 2025
Computational Prediction of Single-Domain Immunoglobulin Aggregation Propensities Facilitates Discovery and Humanization of Recombinant NanobodiesFelix Klaus Geyer, Julian Borbeck, Wiktoria Palka, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|January 5, 2026
Targeting highly attenuated IL-18 to PD-1 for enhanced anti-tumor activityXueyuan Zhou, Felix Klaus Geyer, Jeffrey Takimoto, et al.
Frontiers in Immunology|March 8, 2024
Using protein geometry to optimize cytotoxicity and the cytokine window of a ROR1 specific T cell engagerXueyuan Zhou, Felix Klaus Geyer, Dominic Happel, et al.
Antibodies (Basel, Switzerland)|September 22, 2025
Computational Prediction of Single-Domain Immunoglobulin Aggregation Propensities Facilitates Discovery and Humanization of Recombinant NanobodiesFelix Klaus Geyer, Julian Borbeck, Wiktoria Palka, et al.
Pageof 1